Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases, Aldo e Cele Daccò Ranica, Bergamo, Italy.
N Engl J Med. 2011 Jul 28;365(4):295-306. doi: 10.1056/NEJMoa1101273. Epub 2011 Jul 14.
Focal segmental glomerulosclerosis is a kidney disease that is manifested as the nephrotic syndrome. It is often resistant to glucocorticoid therapy and progresses to end-stage renal disease in 50 to 70% of patients. Genetic studies have shown that familial focal segmental glomerulosclerosis is a disease of the podocytes, which are major components of the glomerular filtration barrier. However, the molecular cause in over half the cases of primary focal segmental glomerulosclerosis is unknown, and effective treatments have been elusive.
We performed whole-genome linkage analysis followed by high-throughput sequencing of the positive-linkage area in a family with autosomal recessive focal segmental glomerulosclerosis (index family) and sequenced a newly discovered gene in 52 unrelated patients with focal segmental glomerulosclerosis. Immunohistochemical studies were performed on human kidney-biopsy specimens and cultured podocytes. Expression studies in vitro were performed to characterize the functional consequences of the mutations identified.
We identified two mutations (A159P and Y695X) in MYO1E, which encodes a nonmuscle class I myosin, myosin 1E (Myo1E). The mutations in MYO1E segregated with focal segmental glomerulosclerosis in two independent pedigrees (the index family and Family 2). Patients were homozygous for the mutations and did not have a response to glucocorticoid therapy. Electron microscopy showed thickening and disorganization of the glomerular basement membrane. Normal expression of Myo1E was documented in control human kidney-biopsy specimens in vivo and in glomerular podocytes in vitro. Transfection studies revealed abnormal subcellular localization and function of the A159P-Myo1E mutant. The Y695X mutation causes loss of calmodulin binding and of the tail domains of Myo1E.
MYO1E mutations are associated with childhood-onset, glucocorticoid-resistant focal segmental glomerulosclerosis. Our data provide evidence of a role of Myo1E in podocyte function and the consequent integrity of the glomerular filtration barrier.
局灶节段性肾小球硬化症是一种表现为肾病综合征的肾脏疾病。它通常对糖皮质激素治疗有抗性,并且在 50%至 70%的患者中进展为终末期肾病。遗传研究表明,家族性局灶节段性肾小球硬化症是一种足细胞疾病,足细胞是肾小球滤过屏障的主要组成部分。然而,超过一半的原发性局灶节段性肾小球硬化症的分子病因尚不清楚,并且有效的治疗方法一直难以捉摸。
我们对一个常染色体隐性局灶节段性肾小球硬化症(索引家族)的家族进行了全基因组连锁分析,然后对阳性连锁区域进行了高通量测序,并对 52 名局灶节段性肾小球硬化症患者进行了新发现基因的测序。对人肾活检标本和培养的足细胞进行了免疫组织化学研究。在体外进行了表达研究,以表征鉴定出的突变的功能后果。
我们在编码非肌肉 I 类肌球蛋白,肌球蛋白 1E(Myo1E)的 MYO1E 中发现了两个突变(A159P 和 Y695X)。MYO1E 中的突变在两个独立的家系(索引家族和家族 2)中与局灶节段性肾小球硬化症分离。患者为突变纯合子,且对糖皮质激素治疗无反应。电子显微镜显示肾小球基底膜增厚和排列紊乱。体内正常表达的 Myo1E 在人肾活检标本和体外肾小球足细胞中均有记录。转染研究显示 A159P-Myo1E 突变体的亚细胞定位和功能异常。Y695X 突变导致钙调蛋白结合和 Myo1E 的尾部结构域缺失。
MYO1E 突变与儿童期发病、糖皮质激素抵抗的局灶节段性肾小球硬化症有关。我们的数据提供了 Myo1E 在足细胞功能中的作用以及肾小球滤过屏障完整性的证据。